TIF
Issue 62 – March 2013
Latest News:
- ‘FAiTh – Fight Against Thalassemia Association’ presents its activities for January 2020
- Renzo Galanello Fellowship Programme 2020
- FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia
- Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)
- Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany
